跳到正文
Molence· @MolenceBio · X·· 17 天前AI 评分54
AI 导读

Molence Bio 报告称,利用第一轮实验结果指导下一轮设计,使 4-1BB 的功能命中率从 7% 提升到 85%。第一轮 30 个设计中有 2 个功能命中,第二轮 60 个中有 51 个命中,并以 VHH-Fc 融合形式测试;在 0.03 nM 下,51 个第二轮激动剂中有 48 个超过 Utomilumab 阳性对照的平均激活水平。

正文 · 原文

5/15 🔁 Experimental feedback raised the 4-1BB functional hit rate from 7% to 85% in one additional design round.

We used first-round results to guide the next round, testing designs as VHH-Fc fusions:
• Round 1: 2/30 functional hits
• Round 2: 51/60 functional hits

At 0.03 nM, 48 of the 51 second-round agonists exceeded the mean activation of the Utomilumab positive control.

Experimental results guide the next design round—connecting structure prediction, antibody design and wet-lab validation in an iterative workflow.

#ProteinDesign

来源:Molence · x.com